How well do targeted drugs work for EGFR lung cancer?
Part of Cancer clinical trials.
This trial studies whether changes in tiny particles in your blood (called exosomes) can show how well targeted therapy is working for lung cancer with an EGFR mutation. You may be eligible if you have this type of lung cancer and are starting your first treatment with a targeted drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of lung cancer called lung adenocarcinoma.
- Your cancer has a common EGFR mutation (like Ex19Del or L858R) but no other EGFR changes.
- You are about to start your first treatment with a targeted therapy drug, with or without chemotherapy.
- You are between 18 and 80 years old.
- You do not have any other type of cancer now or in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses artificial intelligence (AI) to analyze your medical images, genetic tests, and pathology reports to see how well targeted therapy (EGFR-TKI) works after lung cancer surgery. It may help doctors better predict treatment outcomes.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
This study uses leftover tissue samples from people with EGFR-mutant non-small cell lung cancer to test how well different drugs work against their tumor cells. It may help guide future treatment decisions.
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
This study tests if regular blood tests can help guide chemotherapy treatment before surgery for people with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It aims to see if these blood tests can show how well the cancer is responding, potentially allowing doctors to adjust treatment for better outcomes.
This trial tests whether using a blood test (ctDNA) to guide targeted therapy after surgery can improve outcomes for patients with stage II-IIIA non-small cell lung cancer that has an EGFR mutation. If you qualify, you may receive a targeted pill (osimertinib) based on your ctDNA results.
Hear when a new EGFR Activating Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.